Table 2.
Baseline characteristics of the subjects according to follow-up outcomes
| Variables | Subjects developed NAFLD (n = 1390) | Subjects did not develop NAFLD (n = 3149) | P |
|---|---|---|---|
| Gender (male/female, n) | 1109/281 | 1887/1262 | < 0.001 |
| Age (years) | 41.0(34.0–51.0) | 41.0 (35.0–51.0) | 0.226 |
| BMI (kg/m2) | 23.9 (22.2–25.3) | 21.5 (19.9–23.3) | < 0.001 |
| SBP (mmHg) | 122.0 (114.0–131.0) | 116.0 (107.0–126.0) | < 0.001 |
| DBP (mmHg) | 78.0 (72.0–84.0) | 74.0 (68.0–80.0) | < 0.001 |
| WC (cm) | 82.0 (77.0–87.0) | 74.0 (69.0–80.0) | < 0.001 |
| TyG | 8.58 (8.25–8.91) | 8.21 (7.91–8.54) | < 0.001 |
| BUN (μmol/l) | 5.03 (4.23–5.86) | 4.95 (4.19–5.75) | 0.029 |
| Cr (μmol/l) | 75.0 (65.0–83.0) | 70.0 (59.0–80.0) | < 0.001 |
| FPG (mmol/l) | 4.47 (4.15–4.82) | 4.43 (4.14–4.77) | 0.114 |
| UA (μmol/l) | 347.0 (294.0–401.0) | 301.0 (245.0–356.0) | < 0.001 |
| AST (U/l) | 20.0 (17.0–24.0) | 19.0 (16.0–22.0) | < 0.001 |
| ALT (U/l) | 26.0 (19.0–37.0) | 19.0 (14.0–26.0) | < 0.001 |
| y-GGT (U/l) | 21.0 (15.0–33.0) | 15.0 (11.0–22.0) | < 0.001 |
| TC (mmol/l) | 4.77 (4.17–5.41) | 4.61 (4.03–5.24) | < 0.001 |
| TG (mmol/l) | 1.48 (1.10–2.04) | 1.03 (0.79–1.39) | < 0.001 |
| HDL-C (mmol/l) | 1.20 (1.05–1.43) | 1.33 (1.10–1.64) | < 0.001 |
| LDL-C (mmol/l) | 2.73 (2.26–3.26) | 2.52 (2.04–3.05) | < 0.001 |
| Apo-A1 (g/l) | 1.26 (1.11–1.45) | 1.35 (1.16–1.53) | < 0.001 |
| Apo-B (g/l) | 0.95 (0.80–1.14) | 0.86 (0.72–1.03) | < 0.001 |
| eGFR (ml/(min·1.73 m2)) | 108.1 (96.5–121.9) | 110.8 (98.4–125.8) | < 0.001 |